Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

LONDON, Nov. 23, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission. The annual report can be found on Autolus' investor relations website at https://www.autolus.com/investor-relations/financial-information/sec-filings.

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com

     
              Investor contact:  
     
              International Media Contact:                    
     
              U.S. Media Contact:



     S.A. Noonan Communications    
     JW Communications                                          
     Rx Communications Group, LLC



     Susan A. Noonan               
     Julia Wilson                                               
     Paula Schwartz



     +1-212-966-3650                                                 
           +44 (0)7818 430877 
     + 1-917-322-2216



     
              susan@sanoonan.com 
     
              juliawilsonuk@gmail.com                         
     
              pschwartz@rxir.com

View original content:http://www.prnewswire.com/news-releases/autolus-therapeutics-submits-fiscal-year-2018-form-20-f-300754699.html

SOURCE Autolus Therapeutics plc